Detalles de la búsqueda
1.
Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer.
Br J Cancer
; 130(8): 1377-1387, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38396173
2.
Pharmacokinetics of the Akt Serine/Threonine Protein Kinase Inhibitor, Capivasertib, Administered to Healthy Volunteers in the Presence and Absence of the CYP3A4 Inhibitor Itraconazole.
Clin Pharmacol Drug Dev
; 12(9): 856-862, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37449963
3.
Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.
NPJ Breast Cancer
; 9(1): 64, 2023 Aug 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-37543694
4.
AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kß/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors.
Oncogene
; 41(46): 5046-5060, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36241868
5.
Placental growth factor neutralising antibodies give limited anti-angiogenic effects in an in vitro organotypic angiogenesis model.
Angiogenesis
; 13(4): 337-47, 2010 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-20953695
6.
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.
NPJ Breast Cancer
; 9(1): 69, 2023 Aug 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-37596288
7.
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.
NPJ Breast Cancer
; 9(1): 76, 2023 Sep 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-37726304
8.
Mixed micelles of lipoic acid-chitosan-poly(ethylene glycol) and distearoylphosphatidylethanolamine-poly(ethylene glycol) for tumor delivery.
Eur J Pharm Sci
; 101: 228-242, 2017 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28163163
9.
Inhibition of oxidative phosphorylation suppresses the development of osimertinib resistance in a preclinical model of EGFR-driven lung adenocarcinoma.
Oncotarget
; 7(52): 86313-86325, 2016 Dec 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-27861144
10.
Utilization of Structure-Based Design to Identify Novel, Irreversible Inhibitors of EGFR Harboring the T790M Mutation.
ACS Med Chem Lett
; 7(5): 514-9, 2016 May 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-27190603
11.
In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib.
Pharmacol Res Perspect
; 3(5): e00175, 2015 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-26516587
12.
AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.
Cancer Discov
; 4(9): 1046-61, 2014 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-24893891
13.
Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR).
J Med Chem
; 56(17): 7025-48, 2013 Sep 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-23930994
14.
MEDI0639: a novel therapeutic antibody targeting Dll4 modulates endothelial cell function and angiogenesis in vivo.
Mol Cancer Ther
; 11(8): 1650-60, 2012 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-22679110
15.
An antibody targeted to VEGFR-2 Ig domains 4-7 inhibits VEGFR-2 activation and VEGFR-2-dependent angiogenesis without affecting ligand binding.
Mol Cancer Ther
; 10(5): 770-83, 2011 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-21388971
Resultados
1 -
15
de 15
1
Próxima >
>>